Top-News
Dienstag,
26.07.2016 14:05
von
PR Newswire
| Aufrufe: 64
Cynosure Reports Net Income of $6.3 Million on Record Sales of $110.3 Million for the Second Quarter of 2016
Zeitungsständer (Symbolbild).
© AdrianHancu / iStock Editorial / Getty Images Plus / Getty Images
PR Newswire
WESTFORD, Mass., July 26, 2016
WESTFORD, Mass., July 26, 2016 /PRNewswire/ -- Cynosure, Inc. (NASDAQ: CYNO) today reported second-quarter 2016 net income of $6.3 million, or $0.27 per diluted share, an increase of 18.3 percent compared with $5.4 million, or $0.24 per diluted share, for the same period of 2015. On a non-GAAP basis, excluding non-cash unrealized foreign exchange measurement gains and losses and amortization of intangibles, second-quarter net income was $8.6 million, or $0.36 per diluted share, compared with $6.7 million, or $0.30 per diluted share, for the prior-year period. Revenue for the three months ended June 30, 2016 increased 32 percent to a record $110.3 million, compared with $83.7 million in the second quarter of 2015.
Operating income for the 2016 second quarter was $10.5 million, compared with second-quarter 2015 operating income of $7.6 million. On a non-GAAP basis, excluding amortization of intangibles, income from operations for the second quarter of 2016 was $12.6 million, compared with $9.9 million for the prior-year period.
"Our second-quarter performance demonstrates the strong momentum throughout our direct sales distribution network," said President and CEO Michael Davin. "Product revenue in North America increased 46 percent in the second quarter to $59.5 million, reflecting the full U.S. rollout of SculpSure for non-invasive fat reduction earlier this year, as well as significant contributions from our MonaLisa Touch®, PicoSure® and ICON™ products. On the international front, our Asia Pacific subsidiaries saw a 46 percent increase in product revenue, propelled by the late 2015 regulatory approvals of PicoSure in China and SculpSure in Australia. Product revenue from our direct subsidiaries in Europe was up 6 percent year-over-year.
"We delivered solid operational results, as our gross margin increased more than 2 percentage points and we generated cash from operations of $16.3 million, bringing our cash and investments balance at the end of the quarter to $210.3 million," Davin said. "At the same time, we continued to invest in the business, launching a highly targeted direct-to-consumer marketing campaign for SculpSure that is attracting new customers and patients to the Cynosure brand. In the R&D area, through ongoing clinical initiatives, we are investing to expand our products for new aesthetic indications and treatment areas."
Second-Quarter 2016 Financial Results
Revenue was $110.3 million for the second quarter of 2016, an increase of 32 percent from the prior-year period. Product revenue in North America grew 46 percent year-over-year to $59.5 million. International product revenue was $31.1 million, an increase of 8 percent over the year-earlier period. Parts, service and disposables revenue increased 47 percent year-over-year to $19.6 million, primarily reflecting sales of disposable PAC (Patented Applicator for Contouring) keys associated with SculpSure.
Gross margin for the second quarter of 2016 was $65.1 million, or 59.0 percent of revenue, compared with $47.4 million, or 56.6 percent of revenue, for the same period in 2015. On a non-GAAP basis, excluding non-cash charges related to the amortization of intangibles, gross margin for the second quarter of 2016 increased to $66.5 million, or 60.3 percent of revenue, compared with $48.9 million, or 58.4 percent of revenue, in the prior-year period.
Total operating expenses for the second quarter of 2016 increased 37.4 percent to $54.6 million from $39.7 million in the same period in 2015, primarily reflecting the SculpSure launch. Sales and marketing expenses for the second quarter of 2016 were $38.6 million, or 35.0 percent of total revenue, compared with sales and marketing expenses of $26.4 million, or 31.6 percent of total revenue, for the second quarter of 2015. The year-over-year increase reflects the addition of sales, clinical support and marketing personnel, as well as additional marketing investments associated with the SculpSure launch.
Recent Highlights
- Cynosure obtained U.S. Food and Drug Administration 510(k) clearance to market a new Laser Delivery System for PicoSure, the world's first aesthetic picosecond laser. Together with the FDA cleared 532 nm and 755 nm wavelengths, Cynosure's new 1064 nm Laser Delivery System improves the multi-wavelength laser technology for removing the full color spectrum of tattoo inks in fewer treatments.
- Cynosure received a medical device license issued by Health Canada to market SculpSure for non-invasive lipolysis of the abdomen and flanks. This operational milestone continues to broaden SculpSure's availability to new geographic regions.
Business Outlook
"Looking ahead, we expect to successfully execute our growth strategy through targeted marketing, clinical and regulatory initiatives," Davin said. "We begin the second half of 2016 with strong momentum, and we are well positioned to continue to deliver value for all of our stakeholders."
Second-Quarter 2016 Financial Results Conference Call
In conjunction with the announcement of its second-quarter financial results, Cynosure will host a conference call for investors and analysts at 9:00 a.m. ET today. On the call, Michael Davin and Timothy Baker, the Company's Chief Financial Officer, will discuss Cynosure's financial results and provide a business overview. Those who wish to listen to the conference call webcast should visit the "Investors" section of the Company's website at www.cynosure.com. The live call can also be accessed by dialing (877) 709-8155 or (201) 689-8881. If you are unable to listen to the live call, the webcast will be archived for one year on the Company's website.
About Cynosure, Inc.
Cynosure develops, manufactures, and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, reduce fat through non-invasive and minimally invasive laser lipolysis, reduce cellulite, clear nails infected by toe fungus, ablate sweat glands and improve gynecological health. Cynosure also markets radiofrequency energy-sourced medical devices for precision surgical applications such as facial plastic and general surgery, gynecology, ear, nose, and throat procedures, ophthalmology, oral and maxillofacial surgery, podiatry and proctology. Cynosure's product portfolio is composed of a broad range of energy sources including Alexandrite, diode, Nd:YAG, picosecond, pulse dye, Q-switched lasers, intense pulsed light and radiofrequency technology. Cynosure sells its products globally under the Cynosure, Palomar, ConBio and Ellman brand names through a direct sales force in the United States, Canada, France, Morocco, Germany, Spain, the United Kingdom, Australia, China, Japan and Korea, and through international distributors in approximately 120 other countries. For corporate or product information, visit Cynosure's website at www.cynosure.com.
Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for Cynosure, Inc., including Cynosure's expectations with respect to timing and success of product launches and expansions, regulatory clearances and international registrations, as well as other statements containing the words, "believes," "looks forward," "anticipates," "plans," "expects," "will" and similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the market price of Cynosure's stock prevailing from time to time, the nature of other investment opportunities presented to the Company from time to time, the Company's cash flow from operations, levels of demand for procedures performed with Cynosure products and for Cynosure products themselves, competition in the aesthetic laser industry, general business and economic conditions, effects of acquisitions that Cynosure has made or may make, Cynosure's ability to develop and commercialize new products, including the MonaLisa Touch and SculpSure products, Cynosure's reliance on sole source suppliers, the inability to accurately predict the timing or outcome of regulatory decisions, and economic, market, technological and other factors described in Item 1A of Part II (Risk Factors) of our Quarterly Report on Form 10-Q for the three months ended March 31, 2016. In addition, the forward-looking statements included in this press release represent Cynosure's views as of the date of this press release. Cynosure anticipates that subsequent events and developments will cause its views to change. However, although Cynosure may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Cynosure's views as of any date subsequent to the date of this press release.
| Consolidated Statements of Income (Unaudited) | | | | | ||||||||||||||||||
| (In thousands, except per share data) | | | | | | |||||||||||||||||
| | | | | | | | ||||||||||||||||
| | | Three Months Ended June 30, | | Six Months Ended June 30, | ||||||||||||||||||
| | | 2016 | 2015 | | 2016 | 2015 | ||||||||||||||||
| | | | | | | | ||||||||||||||||
| Revenues | $ 110,343 | $ 83,694 | | $ 205,007 | $ 158,606 | |||||||||||||||||
| Cost of revenues | 45,286 | 36,338 | | 84,530 | 68,477 | |||||||||||||||||
| Gross profit | 65,057 | 47,356 | | 120,477 | 90,129 | |||||||||||||||||
| | | | | | | | ||||||||||||||||
| Operating expenses | | | | | | |||||||||||||||||
| | Selling and marketing | 38,574 | 26,426 | | 74,165 | 52,122 | ||||||||||||||||
| | Research and development | 6,965 | 5,251 | | 14,078 | 11,209 | ||||||||||||||||
| | Amortization of intangible assets acquired | 684 | 736 | | 1,373 | 1,472 | ||||||||||||||||
| | General and administrative | 8,334 | 7,302 | | 15,910 | 15,632 | ||||||||||||||||
| | | | | | | | ||||||||||||||||
| Total operating expenses | 54,557 | 39,715 | | 105,526 | 80,435 | |||||||||||||||||
| | | | | | | | ||||||||||||||||
| Income from operations | 10,500 | 7,641 | | 14,951 | 9,694 | |||||||||||||||||
| | | | | | | | ||||||||||||||||
| | Interest expense, net | (392) | (430) | | (804) | (832) | ||||||||||||||||
| | Other (expense) income, net | (277) | 484 | | 383 | (1,179) | ||||||||||||||||
| | | | | | | | ||||||||||||||||
| Income before income taxes | 9,831 | 7,695 | | 14,530 | 7,683 | |||||||||||||||||
| | | | | | | | ||||||||||||||||
| | Income tax provision | 3,491 | 2,337 | | 5,343 | 2,333 | ||||||||||||||||
| | | | | | | | ||||||||||||||||
| Net income | $ 6,340 | $ 5,358 | | $ 9,187 | $ 5,350 | |||||||||||||||||
| | | | | | | | ||||||||||||||||
| | | | | | | | ||||||||||||||||
| Diluted net income per share | $ 0.27 | $ 0.24 | | $ 0.39 Werbung Mehr Nachrichten zur Cynosure Cl. A Aktie kostenlos abonnieren
E-Mail-Adresse
Bitte überprüfe deine die E-Mail-Adresse.
Benachrichtigungen von ARIVA.DE (Mit der Bestellung akzeptierst du die Datenschutzhinweise) -1  Vielen Dank, dass du dich für unseren Newsletter angemeldet hast. Du erhältst in Kürze eine E-Mail mit einem Aktivierungslink. Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte. Andere Nutzer interessierten sich auch für folgende News | ||||||||||||||||||
